Work

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps4191

Authors: Jaydira Del Rivero, Kimberly Perez, Susan Michelle Geyer, Maged F. Khalil, Aishwarya Vijendran, Andrea Kordaris-Corkill, Ardaman Shergill, Kristen Renee Spencer, Heloisa P. Soares, Charles D. Lopez, Andrew B. Nixon, Amylou C. Dueck, Jeffrey A. Meyerhardt, Eileen Mary O'Reilly

Institutions: National Institutes of Health, National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic, Lehigh Valley Health Network, University of Chicago, University of Chicago Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Utah, Huntsman Cancer Institute, Oregon Health & Science University, Duke Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Adrenal and Paraganglionic Tumors

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4379282616

Cites:

Cited by: 5

Related to: 10